Compare Stocks

→ Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMFPF Amplifon	$32.20	$30.29	$27.90 ▼ $35.88	$7.29B	0.42	41 shs	N/A
ETNB 89bio	$8.58 -3.8%	$11.09	$6.57 ▼ $22.93	$816.99M	1.04	1.23 million shs	871,176 shs
TGIF SoFi Weekly Income ETF	$97.49 0.0%	$97.49	$92.22 ▼ $99.07	$16.57M	0.29	2,300 shs	3,300 shs
ULGX Urologix		$0.00	$0.00 ▼ $0.00	N/A	0.08	N/A	N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMFPF Amplifon	0.00%	0.00%	+7.80%	+0.63%	-5.29%
ETNB 89bio	-4.19%	-4.80%	-22.43%	-12.89%	-43.18%
TGIF SoFi Weekly Income ETF	0.00%	0.00%	0.00%	+0.23%	+3.16%
ULGX Urologix	0.00%	0.00%	0.00%	0.00%	0.00%

Exposed: 10 CENT Crypto to Explode April 20th? (Ad)

Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin

Click For My #1 FREE Crypto for 2024

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMFPF Amplifon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	1.9208 of 5 stars	4.4	1.0	0.0	0.0	1.9	1.7	0.0
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMFPF Amplifon	3.00	Buy	N/A	N/A
ETNB 89bio	2.71	Moderate Buy	$29.00	238.00% Upside
TGIF SoFi Weekly Income ETF	0.00	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest TGIF, ULGX, ETNB, and AMFPF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/22/2024	ETNB 89bio	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$30.00
4/5/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00
3/27/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/13/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00
3/6/2024	ETNB 89bio	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$29.00 ➝ $37.00
3/5/2024	ETNB 89bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
3/4/2024	ETNB 89bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$29.00
3/1/2024	ETNB 89bio	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$15.00 ➝ $14.00
3/1/2024	ETNB 89bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $31.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMFPF Amplifon	$2.23B	N/A	$1.97 per share	16.34	$4.84 per share	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	$5.75 per share	N/A
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMFPF Amplifon	$188.09M	$0.78	41.28	27.29	N/A	7.44%	16.57%	4.83%	N/A
ETNB 89bio	-$142.19M	-$2.01	N/A	N/A	N/A	N/A	-31.01%	-27.84%	5/2/2024 (Estimated)
TGIF SoFi Weekly Income ETF	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest TGIF, ULGX, ETNB, and AMFPF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	ETNB 89bio	-$0.49	-$0.50	-$0.01	-$0.50	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMFPF Amplifon	N/A	N/A	N/A	N/A	N/A
ETNB 89bio	N/A	N/A	N/A	N/A	N/A
TGIF SoFi Weekly Income ETF	$4.03	4.13%	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMFPF Amplifon	0.61	0.48	0.41
ETNB 89bio	0.05	20.04	20.04
TGIF SoFi Weekly Income ETF	N/A	N/A	N/A
ULGX Urologix	N/A	N/A	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AMFPF Amplifon	N/A
ETNB 89bio	N/A
TGIF SoFi Weekly Income ETF	N/A
ULGX Urologix	N/A

Insider Ownership

Company	Insider Ownership
AMFPF Amplifon	N/A
ETNB 89bio	4.40%
TGIF SoFi Weekly Income ETF	N/A
ULGX Urologix	8.50%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AMFPF Amplifon	13,195	N/A	N/A	Not Optionable
ETNB 89bio	70	95.22 million	91.04 million	Optionable
TGIF SoFi Weekly Income ETF	N/A	170,000	N/A	Not Optionable
ULGX Urologix	61	N/A	N/A	Not Optionable

TGIF, ULGX, ETNB, and AMFPF Headlines

Source	Headline
	Latest Market Study \| Anti-Snoring Devices Market Size, Share, Trends, Industry Analysis & Forecasts, 2023-2030 finance.yahoo.com - November 15 at 10:42 PM
	Suoxinda Holdings Ltd (3680) investing.com - July 29 at 1:06 PM
	Create Capital Vietnam Limited JSC (CRC) investing.com - July 13 at 11:30 PM
	Benign Prostate Hyperplasia (BPH) Treatment Market Report 2023: Product Launches Continue to Boost Market finance.yahoo.com - May 1 at 2:38 AM
	Urologix, Inc. (ULGX) Stock Historical Prices & Data - Yahoo Finance finance.yahoo.com - March 7 at 7:35 AM
	Urologix Year to Date Total Returns (Daily) ycharts.com - December 18 at 11:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Amplifon

OTCMKTS:AMFPF

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.

89bio

NASDAQ:ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.

SoFi Weekly Income ETF

NYSEARCA:TGIF

The SoFi Weekly Income ETF (TGIF) is an exchange-traded fund that mostly invests in broad credit fixed income. The fund is the first actively managed USD-denominated fixed income ETF aiming to provide weekly distributions to investors. TGIF was launched on Oct 1, 2020 and is managed by SoFi.

Urologix

OTCMKTS:ULGX

Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to benign prostatic hyperplasia (BPH) in the United States. The company offers Cooled ThermoTherapy, which produces targeted microwave energy combined with a cooling mechanism to protect healthy tissue and enhance patient comfort. It also provides Prostiva RF Therapy System that delivers radio frequency energy directly into the prostate to destroy prostate tissue, reduce constriction of the urethra, and relieve BPH symptoms. It serves patients and clinicians. Urologix, Inc. was founded in 1991 and is based in Minneapolis, Minnesota.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial